Clinical Trial Detail

NCT ID NCT01869803
Title Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Recruitment Approved for marketing
Gender both
Phase Phase I
Variant Requirements No
Sponsors Comprehensive Cancer Center of Wake Forest University
Indications

acute promyelocytic leukemia

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin

Age Groups: adult

No variant requirements are available.